Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 juil. 2022 17h09 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 12, 2022, the Compensation Committee of Crinetics’ Board of Directors granted...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 juin 2022 16h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted...
Crinetics Presents Clinical and Research Results at ENDO 2022
08 juin 2022 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational...
Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
07 juin 2022 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel...
Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts
25 mai 2022 07h00 HE
|
Crinetics Pharmaceuticals, Inc.
Patient Studies in Cushing’s Disease and Congenital Adrenal Hyperplasia to Initiate Later this Year Management Hosting Webcast and Conference Call Today to Discuss Findings at 8:00 a.m. Eastern Time ...
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
12 mai 2022 16h42 HE
|
Crinetics Pharmaceuticals, Inc.
Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated Top-Line Data Readouts in 2023Clinical Trial of...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 mai 2022 16h18 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering
18 avr. 2022 16h01 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
12 avr. 2022 23h50 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 avr. 2022 17h15 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 11, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...